Product name as reported
Umeclidinium Bromide Vilanterol Trifenatate: adverse event reports filed with FDA
798 reports list it as a suspect or interacting product, 2014–2026.
- 798
- reports as suspect product
- 0% of all reports · about 67 a year
- 137
- reports, 12 months to June 2026
- 113 in the 12 months before
- 89%
- marked serious by the reporter
- 57.4% across all reports
- 28.6%
- record death among outcomes, as reported
- 228 reports · not verified by FDA
798 adverse event reports received by FDA list the product name "Umeclidinium Bromide Vilanterol Trifenatate" as reporters wrote it as a suspect or interacting product, from July 2014 to June 2026. A further 987 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 137 reports listed it, up 21% from 113 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 67 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded dyspnoea (44.1%), wheezing (40.5%) and condition aggravated (34.5%). A report can list several reactions, so shares add to more than 100%; 342 different terms appear across these reports. Dyspnoea is recorded in 44.1% of these reports, against 2.7% of all reports in the database.
89% of the reports are marked serious by the reporter; 28.6% record death among the outcomes and 47.4% record hospitalisation, as reported. 44% of the reports came from other health professionals, and the largest patient age group is 75 and over (24.1%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Umeclidinium Bromide Vilanterol Trifenatate reports recording the termall reports in the database
- Dyspnoeashortness of breath44.1%352
- Wheezingwheezing40.5%323
- Condition aggravatedthe condition being treated got worse34.5%275
- Asthmaasthma33.5%267
- Chronic obstructive pulmonary diseaseCOPD, a long-term lung disease27.9%223
- Obstructive airways disorder27.6%220
- Nauseafeeling sick23.8%190
- Vomitingbeing sick21.7%173
- Full blood count abnormal20.8%166
- Off label useused for a purpose or in a way not on the label20.3%162
- Abdominal distensiona bloated abdomen19.7%157
- Constipationconstipation18.5%148
- Abdominal painstomach or belly pain18.2%145
- Ascitesfluid in the abdomen17.7%141
- Lung disordera lung problem, type not specified17.3%138
- Coughcough16.9%135
- Thrombosis16.9%135
- Productive cougha cough with phlegm16.8%134
- Pulmonary embolisma blood clot in the lung16.8%134
- Sepsisa severe body-wide response to infection16.5%132
- General physical health deteriorationgeneral decline in health16.4%131
- Pulmonary fibrosis16.4%131
- Pneumonialung infection16.3%130
- Appendicitis16.2%129
- Oedema peripheralswelling of the legs, ankles or hands16.2%129
- Cardiogenic shockshock from the heart failing to pump16%128
- Appendicolith15.9%127
Top 30 of 342 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 15.7% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Dyspnoea | 109 | 13.7% |
| Chronic obstructive pulmonary disease | 93 | 11.7% |
| Asthma | 31 | 3.9% |
| Emphysema | 2 | 0.3% |
| Hypersensitivity pneumonitis | 2 | 0.3% |
| Lung disorder | 2 | 0.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 798 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Umeclidinium Bromide Vilanterol Trifenatate reports |
|---|---|---|
| Albuterol | 366 | 45.9% |
| Prednisone | 303 | 38% |
| Umeclidinium bromide | 274 | 34.3% |
| Breo Ellipta | 246 | 30.8% |
| Ipratropium bromide | 245 | 30.7% |
| Trelegy Ellipta | 245 | 30.7% |
| Albuterol sulfate | 231 | 28.9% |
| Betamethasone | 201 | 25.2% |
| Calcium carbonate | 201 | 25.2% |
| Insulin aspart | 199 | 24.9% |
Other products listed in reports where Umeclidinium Bromide Vilanterol Trifenatate is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Umeclidinium Bromide Vilanterol Trifenatate | All reports |
|---|---|---|
| Reports as suspect product | 798 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 137 | 1,332,454 |
| Marked serious | 89% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 286 | 91 |
| Hospitalisation recorded, per 1,000 reports | 474 | 213 |
| Consumer-filed share | 35% | 45.8% |
| Top term, share of reports | Dyspnoea 44.1% | 2.7% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Umeclidinium Bromide Vilanterol Trifenatate reports
How many adverse event reports has FDA received for Umeclidinium Bromide Vilanterol Trifenatate?
798 reports list Umeclidinium Bromide Vilanterol Trifenatate as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 137 of them arrived in the latest 12 months. Another 987 list it only as a concomitant medication.
What reactions are recorded in Umeclidinium Bromide Vilanterol Trifenatate reports?
dyspnoea (44.1%), wheezing (40.5%), condition aggravated (34.5%), asthma (33.5%) and chronic obstructive pulmonary disease (27.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Umeclidinium Bromide Vilanterol Trifenatate was responsible.
How serious are the reports?
89% are marked serious by the reporter. Among the outcomes recorded, 28.6% of reports include death and 47.4% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (44%), consumer or non-health professional (35%) and physician (19.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Umeclidinium Bromide Vilanterol Trifenatate rising?
137 reports in the 12 months to June 2026, up 21% from 113 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Umeclidinium Bromide Vilanterol Trifenatate was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Umeclidinium Bromide Vilanterol Trifenatate?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Umeclidinium Bromide Vilanterol Trifenatate as a suspect or interacting product; reports listing it only as a concomitant medication (987) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.